Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies | Synapse
March 25, 2026Open Access
Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
Key Points
The study aims to evaluate the clinical benefit of zanidatamab for treating HER2-positive salivary gland cancer (SGC).
Combined analysis of early-phase studies
Evaluation of treatment outcomes in HER2-positive SGC patients
Assessment of clinical benefit despite small sample size
Findings indicate clinical benefit from zanidatamab treatment
Results suggest effectiveness for patients with unresectable or metastatic HER2-positive SGC
Abstract
Although the sample size is small, these findings support the clinical benefit of zanidatamab treatment for HER2-positive SGC.